BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
BioArctic (NASDAQ Stockholm: BIOA B) announced that its founder, Professor Lars Lannfelt, will receive the prestigious 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering work in Alzheimer's disease research and the development of lecanemab.
Professor Lannfelt, who founded BioArctic in 2003 with Pär Gellerfors, made groundbreaking discoveries about the role of amyloid-beta protein in Alzheimer's disease. These findings led to the development of lecanemab, an antibody treatment that targets specific forms of amyloid-beta in the brain, developed in collaboration with Eisai. The treatment showed positive results in the global Phase 3 Clarity AD trial.
The award ceremony will take place in Bonn in November 2025. The prize, awarded biennially since 2011, recognizes outstanding research in neurodegenerative disorders.
BioArctic (NASDAQ Stoccolma: BIOA B) ha annunciato che il suo fondatore, Professor Lars Lannfelt, riceverà il prestigioso Premio Hartwig Piepenbrock-DZNE 2025 per il suo lavoro pionieristico nella ricerca sull'Alzheimer e nello sviluppo di lecanemab.
Il Professor Lannfelt, che ha fondato BioArctic nel 2003 insieme a Pär Gellerfors, ha fatto scoperte rivoluzionarie sul ruolo della proteina amiloide-beta nella malattia di Alzheimer. Questi risultati hanno portato allo sviluppo di lecanemab, un trattamento con anticorpi che mira a specifiche forme di amiloide-beta nel cervello, sviluppato in collaborazione con Eisai. Il trattamento ha mostrato risultati positivi nel trial globale di Fase 3 Clarity AD.
La cerimonia di premiazione si terrà a Bonn nel novembre 2025. Il premio, assegnato biennalmente dal 2011, riconosce ricerche eccezionali sulle malattie neurodegenerative.
BioArctic (NASDAQ Estocolmo: BIOA B) anunció que su fundador, el Profesor Lars Lannfelt, recibirá el prestigioso Premio Hartwig Piepenbrock-DZNE 2025 por su trabajo pionero en la investigación del Alzheimer y el desarrollo de lecanemab.
El Profesor Lannfelt, quien fundó BioArctic en 2003 junto con Pär Gellerfors, realizó descubrimientos innovadores sobre el papel de la proteína amiloide-beta en la enfermedad de Alzheimer. Estos hallazgos condujeron al desarrollo de lecanemab, un tratamiento con anticuerpos que se dirige a formas específicas de amiloide-beta en el cerebro, desarrollado en colaboración con Eisai. El tratamiento mostró resultados positivos en el ensayo global de Fase 3 Clarity AD.
La ceremonia de entrega de premios se celebrará en Bonn en noviembre de 2025. El premio, otorgado bienalmente desde 2011, reconoce investigaciones sobresalientes en trastornos neurodegenerativos.
BioArctic (나스닥 스톡홀름: BIOA B)는 창립자 라스 란펠트 교수가 알츠하이머병 연구와 레카네맙 개발에 대한 선구적인 공로로 2025 하트비히 피펜브록-DZNE 상을 수상한다고 발표했습니다.
란펠트 교수는 2003년 Pär Gellerfors와 함께 BioArctic을 설립했으며, 알츠하이머병에서 아밀로이드 베타 단백질의 역할에 대한 획기적인 발견을 했습니다. 이 발견은 Eisai와 협력하여 개발한 뇌 내 특정 아밀로이드 베타 형태를 표적으로 하는 항체 치료제 레카네맙 개발로 이어졌습니다. 이 치료법은 글로벌 3상 임상시험 Clarity AD에서 긍정적인 결과를 보였습니다.
시상식은 2025년 11월 본에서 열릴 예정입니다. 2011년부터 격년으로 수여되는 이 상은 신경퇴행성 질환 분야의 뛰어난 연구를 인정합니다.
BioArctic (NASDAQ Stockholm : BIOA B) a annoncé que son fondateur, le professeur Lars Lannfelt, recevra le prestigieux prix Hartwig Piepenbrock-DZNE 2025 pour ses travaux pionniers sur la maladie d'Alzheimer et le développement de lecanemab.
Le professeur Lannfelt, qui a fondé BioArctic en 2003 avec Pär Gellerfors, a réalisé des découvertes majeures sur le rôle de la protéine amyloïde-bêta dans la maladie d'Alzheimer. Ces résultats ont conduit au développement de lecanemab, un traitement par anticorps ciblant des formes spécifiques d'amyloïde-bêta dans le cerveau, développé en collaboration avec Eisai. Ce traitement a montré des résultats positifs lors de l'essai mondial de phase 3 Clarity AD.
La cérémonie de remise des prix aura lieu à Bonn en novembre 2025. Ce prix, décerné tous les deux ans depuis 2011, récompense des recherches exceptionnelles sur les troubles neurodégénératifs.
BioArctic (NASDAQ Stockholm: BIOA B) gab bekannt, dass sein Gründer, Professor Lars Lannfelt, den renommierten Hartwig Piepenbrock-DZNE Preis 2025 für seine bahnbrechenden Arbeiten in der Alzheimer-Forschung und der Entwicklung von Lecanemab erhalten wird.
Professor Lannfelt, der BioArctic 2003 zusammen mit Pär Gellerfors gründete, machte wegweisende Entdeckungen über die Rolle des Amyloid-Beta-Proteins bei Alzheimer. Diese Erkenntnisse führten zur Entwicklung von Lecanemab, einer Antikörperbehandlung, die spezifische Formen von Amyloid-Beta im Gehirn gezielt angreift und in Zusammenarbeit mit Eisai entwickelt wurde. Die Behandlung zeigte positive Ergebnisse in der globalen Phase-3-Studie Clarity AD.
Die Preisverleihung findet im November 2025 in Bonn statt. Der seit 2011 alle zwei Jahre vergebene Preis würdigt herausragende Forschung im Bereich neurodegenerativer Erkrankungen.
- None.
- None.
"I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me throughout my research life," said Professor Lars Lannfelt. "It is inspiring to see how research in this field now has begun to take quantum leaps with the development of treatments such as lecanemab which demonstrated benefits to patients in the global Phase 3 Clarity AD trial using gold standard endpoints. Coupled with the introduction of modern diagnostic methods, I am convinced that we are facing a paradigm shift where, in time, we will be able to offer not just a slowdown in the progression of the disease but eventually be able to halt the disease process."
Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease. These discoveries are the basis for lecanemab, an antibody treatment developed in collaboration with the Japanese company Eisai. By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.
Since 2011, the Hartwig Piepenbrock-DZNE Prize has been awarded every two years for outstanding research on neurodegenerative disorders. The prize is sponsored by the Piepenbrock Group and is awarded in remembrance of its former Chief Executive Officer and Chairman Hartwig Piepenbrock, who passed away after suffering from dementia. Prize winners are selected by an international committee, coordinated by DZNE. On this occasion, the prize will be awarded for the eighth time.
The information was released for public disclosure, through the agency of the contact persons below, on June 26, 2025, at 10.15 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize |
View original content:https://www.prnewswire.com/news-releases/bioarctic-professor-lars-lannfelt-to-receive-the-2025-hartwig-piepenbrock-dzne-prize-302492075.html
SOURCE BioArctic
FAQ
Who is Professor Lars Lannfelt and what did he win the 2025 Hartwig Piepenbrock-DZNE Prize for?
What is lecanemab and how does it work in treating Alzheimer's disease?
When was BioArctic founded and by whom?
When and where will the Hartwig Piepenbrock-DZNE Prize ceremony take place?
